Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Current or former cigarette smokers with a cigarette smoking history of at least 10 pack-years
A diagnosis of stable moderate to severe COPD and stable airway obstruction as defined by the Global Initiative for Chronic Obstructive Lung Disease guidelines and stable airway obstruction.
You may not be if
Patients who have been hospitalized for an acute COPD exacerbation within three months prior to Visit 1
Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the six weeks before Visit 1.
Patients with any clinically significant respiratory conditions other than COPD
Clinical history that suggests that the patient has asthma as opposed to COPD
Chronic use of oxygen therapy ≥ 15 hours/day
Patients with clinically significant cardiovascular conditions
Patients with uncontrolled infection that may place the patient at risk resulting from human immunodeficiency virus (HIV), active hepatitis and/or patients with diagnosed active tuberculosis
Patients with a history of hypersensitivity reaction to inhaled anticholinergics,
Patients with Stage II hypertension, defined as systolic pressure of 160 and above, and/or diastolic pressure of 100 and above
Current diagnosis of cancer other than basal or squamous cell skin cancer
Clareo Health | Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
